Modus Therapeutics Holding AB is a Sweden-based biotechnology company that through the patented polysaccharide sevuparin develops the treatment for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.

• Revenue in SEK (TTM)0.00
• Net income in SEK-14.96m
• Incorporated2011
• Employees2.00

• Location
  Modus Therapeutics Holding ABOlof Palmes gata 29 IVSTOCKHOLM 111 22SwedenSWE
• Websitehttps://www.modustx.com/